Clinical Value of Ezrin Expression in Primary Osteosarcoma
Open Access
- 1 January 2009
- journal article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 41 (3) , 138-144
Abstract
Kim C, et al. Cancer Res Treat. 2009 Sep;41(3):138-144. http://dx.doi.org/10.4143/crt.2009.41.3.138Keywords
This publication has 23 references indexed in Scilit:
- A review of clinical and molecular prognostic factors in osteosarcomaJournal of Cancer Research and Clinical Oncology, 2007
- Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomasVirchows Archiv, 2007
- Ezrin Expression Predicts Survival in Stage IIB OsteosarcomasClinical Orthopaedics and Related Research, 2007
- Ezrin in osteosarcoma: Comparison between conventional high-grade and central low-grade osteosarcomaPathology - Research and Practice, 2006
- Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapyCancer, 2006
- Prognostic Impact of Immunohistochemical Expression of Ezrin in Highly Malignant Soft Tissue SarcomasClinical Cancer Research, 2005
- Ezrin, a key component in tumor metastasisTrends in Molecular Medicine, 2004
- The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasisNature Medicine, 2004
- ERM proteins and merlin: integrators at the cell cortexNature Reviews Molecular Cell Biology, 2002
- Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma IntergroupEuropean Journal of Cancer, 2002